Loading...
New

Antifibrinolytic Drugs Market by Indication (Gynecology, Hereditary Angiedema, Fibrinolytic Response Testing, Surgeries, and Others) and End user (Hospitals & Clinics, Ambulatory Surgical Centers, and Healthcare Specialty Process): Global Opportunity Analysis and Industry Forecast, 2019–2026

A05914
Pages: 165
Dec 2019 | 513 Views
 
Author(s) : Kavita Joshi , Onkar Sumant
Tables: 111
Charts: 34
 

The global antifibrinolytic drugs market was valued at $13,593 million in 2018 and is expected to reach $19,333 million by 2026, registering a CAGR of 4.5% from 2019 to 2026. Antifibrinolytic drugs are used to prevent fibrinolysis or lysis of blood clots or thrombus. Fibrinolysis is a process in which stimulated plasminogen removes excess fibrin to promote fibrin clot formation and wound healing. Further, tissue plasminogen activators and other plasminogen activators are the first line mediators in lysis therapy. Blockers of fibrinolysis act when plasminogen is converted to plasmin, by reversely blocking the lysine binding sites of plasmin or by active inhibition of plasmin via serine protease inhibition. The antifibrinolytic drugs are widely used for inhibition of fibrinolysis and thus, are referred to as lysine analogues. The drugs are used to control massive hemorrhage and for other coagulation disorders. Moreover, antifibrinolytic agents are widely used in the management of mucosal bleeding where there is high fibrinolytic potential such as in oropharynx, nose, GI tract, and uterine-vaginal lining. In hemophilia, antifibrinolytic agents such as tranexamic acid or epsilon aminocaproic acid are generally used in the context of oral bleeding or dental surgery. Most common antifibrinolytic drugs used include tranexamic acid and ε-aminocaproic acid, and the serine protease inhibitor, aprotinin. 

Antifibrinolytics Drug Market

Get more information on this report : Request Sample Pages   

Significant rise in road accidents, accidental trauma, rise in medical surgeries, surge in incidence of angioedema, and growth in high-risk geriatric population across the globe are the major factors that drive the antifibrinolytic drugs market growth. For instance, trauma is the leading cause of mortality in people aged 1 to 65 years, according to the U.S. National Trauma Institute. In addition, as per the WHO, approximately 1.35 million people die each year as a result of road traffic crashes. Antifibrinolytic drugs play a vital role in averting clot lysis and thereby, loss of blood. Further, these drugs are also widely used to prevent heavy menstrual bleeding in women, also known as menorrhagia. These drugs are also used after surgeries such as cardiovascular surgeries and neurosurgeries to prevent enormous blood loss from patient’s body. Considerable surge in prevalence of bleeding disorders propel the antifibrinolytic drugs market growth. However, high cost of these drugs hamper the market growth. Furthermore, increase in research & development for developing novel innovative antifibrinolytic drugs is anticipated to create new opportunities for the market.

Global Antifibrinolytic Drugs Market Segmentation

The antifibrinolytic drugs market is segmented on the basis of indication, end-users, and region. On the basis of indication, it is classified into gynecology, hereditary angiedema, fibrinolytic response testing, surgeries, and others. By end user, it is divided into hospitals & clinics, ambulatory surgical centers, and healthcare specialty process. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Indication segment review

By indication, the gynecology segment accounted for majority of the antifibrinolytic drugs market share in 2018 and is expected to exhibit a prominent growth rate in the near future, owing to the increased adoption of these drugs to prevent menorrhagia i.e. heavy menstrual flow. Further, these drugs are manufactured to reduce bleeding by inhibiting endometrial clot-dissolving enzymes in the uterine lining. Tranexamic acid (TXA) is the most widely used drug for controlling menorrhagia.

Antifibrinolytic Drugs Market
By Indication

Your browser does not support the canvas element.

Surgeries segment is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages   

End user segment review

By end user, the hospitals & clinics segment dominated the antifibrinolytic drugs market in 2018 and is anticipated to maintain its dominance during the forecast period. This is attributed to the increased usage of these drugs in hospitals as most of the surgeries such as cardiovascular and neurosurgeries are performed in hospitals. However, the trauma centers segment is anticipated to grow at the fastest rate owing to the significant increase in road accidents across the globe. Road traffic injury death rates are highest in the African region. Even within high-income countries, people from lower socioeconomic backgrounds are more likely to be involved in road traffic crashes.

Antifibrinolytic Drugs Market
By End User

Your browser does not support the canvas element.

Trauma Centers is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages   

North America accounted for majority of the market share in 2018 and is anticipated to continue this trend during the forecast period. This is attributed to the increased adoption of these drugs by women to control heavy menstrual flow. Moreover, significant rise in surgeries in this region propels the market growth. For instance, in 2018, there were a total of 377,763 cardiovascular surgeries performed in North America. However, the Asia-Pacific region is anticipated to grow at the fastest rate during the forecast period, owing to surge in road accidents in this region. For instance, as per the WHO, more than 90% of road traffic deaths occur in low- and middle-income economies.

Antifibrinolytic Drugs Market
By Region

2026
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 6.1% during 2019-2026.

Get more information on this report : Request Sample Pages   

Comprehensive competitive analysis and profiles of major market players such as Acic Fine Chems, Xanodyne Pharmaceuticals, Aurobindo Pharma Ltd., Akorn, Amerigen Pharms Ltd, Mylan, Pfizer (GenMed), Sanofi, Zydus Cadila, and Takeda are provided in this report.

Key Benefits for Stakeholders:

  • The antifibrinolytic drugs market share and analysis is based on a comprehensive analysis of key developments in the antifibrinolytic drugs industry.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the global market.
  • The study provides an in-depth analysis of the market trends to elucidate the imminent investment pockets.
  • The global antifibrinolytic drugs market trends are studied from 2018 to 2026.
  • Information about key drivers, restrains, and opportunities and their impact analysis on the market size is provided.
  • Porter’s five forces analysis illustrates the potency of buyers and suppliers operating in the industry.
  • The quantitative analysis of the global antifibrinolytic drugs market from 2019 to 2026 is provided to determine the market potential.

Key Market Segments:

By Indication

  • Gynecology
  • Hereditary Angiedema
  • Fibrinolytic Response Testing
  • Surgeries
  • Others

By End User

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Trauma Centers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:  INTRODUCTION

1.1.  Report description
1.2.  Key benefits for stakeholders
1.3.  Key market segments
1.4.  Research methodology

1.4.1.  Secondary research
1.4.2.  Primary research
1.4.3.  Analyst Tools and Models

CHAPTER 2:  EXECUTIVE SUMMARY

2.1.  Key findings of the study
2.2.  CXO perspective

CHAPTER 3:  MARKET OVERVIEW

3.1.  Market definition and scope
3.2.  Key findings

3.2.1.  Top investment pockets

3.3.  Porter’s five forces analysis

3.3.1.  Moderate bargaining power of buyers
3.3.2.  Low bargaining power of suppliers
3.3.3.  Moderate threat of substitutes
3.3.4.  Low threat of new entrants
3.3.5.  Moderate competitive rivalry

3.4.  Top player positioning
3.5.  Market dynamics

3.5.1.  Drivers

3.5.1.1.  Surge in severe road accidents
3.5.1.2.  Significant increase in surgical procedures

3.5.2.  Restraint

3.5.2.1.  High cost of these drugs

3.5.3.  Opportunity

3.5.3.1.  Various growth opportunities in emerging economies

CHAPTER 4:  ANTIFIBRINOLYTIC DRUGS MARKET, BY INDICATION

4.1.  Overview

4.1.1.  Market size and forecast

4.2.  Gynecology

4.2.1.  Key market trends and opportunities
4.2.2.  Market size and forecast
4.2.3.  Market share analysis, by country

4.3.  Hereditary angioedema

4.3.1.  Key market trends and growth opportunities
4.3.2.  Market size and forecast
4.3.3.  Market share analysis, by country

4.4.  Fibrinolytic response testing

4.4.1.  Key market trends and opportunities
4.4.2.  Market size and forecast
4.4.3.  Market share analysis, by country

4.5.  Surgeries

4.5.1.  Key market trends and opportunities
4.5.2.  Market size and forecast
4.5.3.  Market share analysis, by country

4.6.  Others

4.6.1.  Key market trends and opportunities
4.6.2.  Market size and forecast
4.6.3.  Market share analysis, by country

CHAPTER 5:  ANTIFIBRINOLYTIC DRUGS MARKET, BY END USER

5.1.  Overview

5.1.1.  Market size and forecast

5.2.  Hospitals

5.2.1.  Market size and forecast
5.2.2.  Market share analysis, by country

5.3.  Ambulatory Surgery Centers

5.3.1.  Market size and forecast
5.3.2.  Market share analysis, by country

5.4.  Trauma Centers

5.4.1.  Market size and forecast
5.4.2.  Market share analysis, by country

CHAPTER 6:  ANTIFIBRINOLYTIC DRUGS MARKET, BY REGION

6.1.  Overview

6.1.1.  Market size and forecast

6.2.  North America

6.2.1.  Key market trends and opportunities
6.2.2.  Market size and forecast, by country
6.2.3.  Market size and forecast, by indication
6.2.4.  Market size and forecast, by end user
6.2.5.  U.S.

6.2.5.1.  U.S. market size and forecast, by indication
6.2.5.2.  U.S. market size and forecast, by end user

6.2.6.  Canada

6.2.6.1.  Canada market size and forecast, by indication
6.2.6.2.  Canada market size and forecast, by end user

6.2.7.  Mexico

6.2.7.1.  Mexico market size and forecast, by indication
6.2.7.2.  Mexico market size and forecast, by end user

6.3.  Europe

6.3.1.  Key growth factors and opportunities
6.3.2.  Market size and forecast, by country
6.3.3.  Market size and forecast, by indication
6.3.4.  Market size and forecast, by end user

6.3.5.  Germany

6.3.5.1.  Germany market size and forecast, by indication
6.3.5.2.  Germany market size and forecast, by end user

6.3.6.  France

6.3.6.1.  France market size and forecast, by indication
6.3.6.2.  France market size and forecast, by end user

6.3.7.  UK

6.3.7.1.  UK market size and forecast, by indication
6.3.7.2.  UK market size and forecast, by end user

6.3.8.  Italy

6.3.8.1.  Italy market size and forecast, by indication
6.3.8.2.  Italy market size and forecast, by end user

6.3.9.  Rest of Europe

6.3.9.1.  Rest of Europe market size and forecast, by indication
6.3.9.2.  Rest of Europe market size and forecast, by end user

6.4.  Asia-Pacific

6.4.1.  Key growth factors and opportunities.
6.4.2.  Market size and forecast, by country
6.4.3.  Market size and forecast, by indication
6.4.4.  Market size and forecast, by end user
6.4.5.  Japan

6.4.5.1.  Japan market size and forecast, by indication
6.4.5.2.  Japan market size and forecast, by end user

6.4.6.  China

6.4.6.1.  China market size and forecast, by indication
6.4.6.2.  China market size and forecast, by end user

6.4.7.  India

6.4.7.1.  India market size and forecast, by indication
6.4.7.2.  India market size and forecast, by end user

6.4.8.  Rest of Asia-Pacific

6.4.8.1.  Rest of Asia-Pacific market size and forecast, by indication
6.4.8.2.  Rest of Asia - Pacific market size and forecast, by end user

6.5.  LAMEA

6.5.1.  Key growth factors and opportunities
6.5.2.  Market size and forecast, by country
6.5.3.  Market size and forecast, by indication
6.5.4.  Market size and forecast, by end user
6.5.5.  Brazil

6.5.5.1.  Brazil market size and forecast, by indication
6.5.5.2.  Brazil market size and forecast, by end user

6.5.6.  Saudi Arabia

6.5.6.1.  Saudi Arabia market size and forecast, by indication
6.5.6.2.  Saudi Arabia market size and forecast, by end user

6.5.7.  South Africa

6.5.7.1.  South Africa market size and forecast, by indication
6.5.7.2.  South Africa market size and forecast, by end user

6.5.8.  Rest of LAMEA

6.5.8.1.  Rest of LAMEA market size and forecast, by indication
6.5.8.2.  Rest of LAMEA market size and forecast, by end user

CHAPTER 7:  COMPANY PROFILES

7.1.  Akorn Inc.

7.1.1.  Company overview
7.1.2.  Company snapshot
7.1.3.  Operating business segments
7.1.4.  Product Portfolio
7.1.5.  Business performance

7.2.  Aurobindo Pharma Limited

7.2.1.  Company overview
7.2.2.  Company snapshot
7.2.3.  Operating business segments
7.2.4.  Product portfolio
7.2.5.  Business performance

7.3.  Bayer AG

7.3.1.  Company overview
7.3.2.  Company snapshot
7.3.3.  Operating business segments
7.3.4.  Product portfolio
7.3.5.  Business performance

7.4.  Ferring Holding SA

7.4.1.  Company overview
7.4.2.  Company snapshot
7.4.3.  Operating business segments
7.4.4.  Product portfolio
7.4.5.  Business performance

7.5.  Mylan N.V.

7.5.1.  Company overview
7.5.2.  Company snapshot
7.5.3.  Operating business segments
7.5.4.  Product portfolio
7.5.5.  Business performance

7.6.  Novartis International AG (Sandoz)

7.6.1.  Company overview
7.6.2.  Company snapshot
7.6.3.  Operating business segments
7.6.4.  Product portfolio
7.6.5.  Business performance

7.7.  Pfizer Inc.

7.7.1.  Company overview
7.7.2.  Company snapshot
7.7.3.  Operating business segments
7.7.4.  Product portfolio
7.7.5.  Business performance

7.8.  Sanofi S.A.

7.8.1.  Company overview
7.8.2.  Company snapshot
7.8.3.  Operating business segments
7.8.4.  Product portfolio
7.8.5.  Business performance

7.9.  Takeda Pharmaceutical Company Limited

7.9.1.  Company overview
7.9.2.  Company snapshot
7.9.3.  Operating business segments
7.9.4.  Product portfolio
7.9.5.  Business performance

7.10.  Vitruvias Therapeutics Inc.

7.10.1.  Company overview
7.10.2.  Company snapshot
7.10.3.  Operating business segments
7.10.4.  Product portfolio
7.10.5.  Business performance
7.10.1.  Key strategic moves and developments

LIST OF TABLES

TABLE 01.  ANTIFIBRINOLYTIC DRUGS MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 02.  ANTIFIBRINOLYTIC DRUGS MARKET FOR GYNECOLOGY MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 03.  ANTIFIBRINOLYTIC DRUGS MARKET FOR HEREDITARY ANGIOEDEMA, BY REGION, 2018-2026 ($MILLION)
TABLE 04.  ANTIFIBRINOLYTIC DRUGS MARKET FOR FIBRINOLYTIC RESPONSE TESTING, BY REGION, 2018-2026 ($MILLION)
TABLE 05.  ANTIFIBRINOLYTIC DRUGS MARKET FOR SURGERIES, BY REGION, 2018-2026 ($MILLION)
TABLE 06.  ANTIFIBRINOLYTIC DRUGS MARKET FOR OTHERS, BY REGION, 2018-2026 ($MILLION)
TABLE 07.  ANTIFIBRINOLYTIC DRUGS MARKET, BY END USER, 2018-2026 ($MILLION)
TABLE 08.  ANTIFIBRINOLYTIC DRUGS MARKET FOR HOSPITALS, BY REGION, 2018-2026 ($MILLION)
TABLE 09.  ANTIFIBRINOLYTIC DRUGS CORTICOSTEROIDS MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2018-2026 ($MILLION)
TABLE 10.  ANTIFIBRINOLYTIC DRUGS MARKET FOR TRAUMA CENTERS, BY REGION, 2018-2026 ($MILLION)
TABLE 11.  ANTIFIBRINOLYTIC DRUGS MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 12.  NORTH AMERICA ANTIFIBRINOLYTIC DRUGS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE 13.  NORTH AMERICA ANTIFIBRINOLYTIC DRUGS MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 14.  NORTH AMERICA ANTIFIBRINOLYTIC DRUGS MARKET, BY END USER, 2018–2026 ($MILLION),
TABLE 15.  U.S. ANTIFIBRINOLYTIC DRUGS MARKET BY IDICATION, 2018-2026 ($MILLION)
TABLE 16.  U.S. ANTIFIBRINOLYTIC DRUGS MARKET BY END USER, 2018-2026 ($MILLION)
TABLE 17.  CANADA ANTIFIBRINOLYTIC DRUGS MARKET BY IDICATION, 2018-2026 ($MILLION)
TABLE 18.  CANADA ANTIFIBRINOLYTIC DRUGS MARKET BY END USER, 2018-2026 ($MILLION)
TABLE 19.  MEXICO ANTIFIBRINOLYTIC DRUGS MARKET BY IDICATION, 2018-2026 ($MILLION)
TABLE 20.  MEXICO ANTIFIBRINOLYTIC DRUGS MARKET BY END USER, 2018-2026 ($MILLION)
TABLE 21.  EUROPE ANTIFIBRINOLYTIC DRUGS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE 22.  EUROPE ANTIFIBRINOLYTIC DRUGS MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 23.  EUROPE ANTIFIBRINOLYTIC DRUGS MARKET, BY END USER, 2018–2026 ($MILLION),
TABLE 24.  GERMANY ANTIFIBRINOLYTIC DRUGS MARKET BY INDICATION, 2018-2026 ($MILLION)
TABLE 25.  GERMANY ANTIFIBRINOLYTIC DRUGS MARKET BY END USER, 2018-2026 ($MILLION)
TABLE 26.  FRANCE ANTIFIBRINOLYTIC DRUGS MARKET BY IDICATION, 2018-2026 ($MILLION)
TABLE 27.  FRANCE ANTIFIBRINOLYTIC DRUGS MARKET BY END USER, 2018-2026 ($MILLION)
TABLE 28.  UK ANTIFIBRINOLYTIC DRUGS MARKET BY IDICATION, 2018-2026 ($MILLION)
TABLE 29.  UK ANTIFIBRINOLYTIC DRUGS MARKET BY END USER, 2018-2026 ($MILLION)
TABLE 30.  ITALY ANTIFIBRINOLYTIC DRUGS MARKET BY IDICATION, 2018-2026 ($MILLION)
TABLE 31.  ITALY ANTIFIBRINOLYTIC DRUGS MARKET BY END USER, 2018-2026 ($MILLION)
TABLE 32.  REST OF EUROPE ANTIFIBRINOLYTIC DRUGS MARKET BY IDICATION, 2018-2026 ($MILLION)
TABLE 33.  REST OF EUROPE ANTIFIBRINOLYTIC DRUGS MARKET BY END USER, 2018-2026 ($MILLION)
TABLE 34.  ASIA-PACIFIC ANTIFIBRINOLYTIC DRUGS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE 35.  ASIA-PACIFIC ANTIFIBRINOLYTIC DRUGS MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 36.  ASIA-PACIFIC ANTIFIBRINOLYTIC DRUGS MARKET, BY END USER, 2018–2026 ($MILLION),
TABLE 37.  JAPAN ANTIFIBRINOLYTIC DRUGS MARKET BY IDICATION, 2018-2026 ($MILLION)
TABLE 38.  JAPAN ANTIFIBRINOLYTIC DRUGS MARKET BY END USER, 2018-2026 ($MILLION)
TABLE 39.  CHINA ANTIFIBRINOLYTIC DRUGS MARKET BY IDICATION, 2018-2026 ($MILLION)
TABLE 40.  CHINA ANTIFIBRINOLYTIC DRUGS MARKET BY END USER, 2018-2026 ($MILLION)
TABLE 41.  INDIA ANTIFIBRINOLYTIC DRUGS MARKET BY IDICATION, 2018-2026 ($MILLION)
TABLE 42.  INDIA ANTIFIBRINOLYTIC DRUGS MARKET BY END USER, 2018-2026 ($MILLION)
TABLE 43.  REST OF ASIA- PACIFIC ANTIFIBRINOLYTIC DRUGS MARKET BY IDICATION, 2018-2026 ($MILLION)
TABLE 44.  REST OF ASIA- PACIFIC ANTIFIBRINOLYTIC DRUGS MARKET BY END USER, 2018-2026 ($MILLION)
TABLE 45.  LAMEA ANTIFIBRINOLYTIC DRUGS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE 46.  LAMEA ANTIFIBRINOLYTIC DRUGS MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 47.  LAMEA ANTIFIBRINOLYTIC DRUGS MARKET, BY END USER, 2018–2026 ($MILLION),
TABLE 48.  BRAZIL ANTIFIBRINOLYTIC DRUGS MARKET BY IDICATION, 2018-2026 ($MILLION)
TABLE 49.  BRAZIL ANTIFIBRINOLYTIC DRUGS MARKET BY END USER, 2018-2026 ($MILLION)
TABLE 50.  SAUDI ARABIA ANTIFIBRINOLYTIC DRUGS MARKET BY IDICATION, 2018-2026 ($MILLION)
TABLE 51.  SAUDI ARABIA ANTIFIBRINOLYTIC DRUGS MARKET BY END USER, 2018-2026 ($MILLION)
TABLE 52.  SOUTH AFRICA ANTIFIBRINOLYTIC DRUGS MARKET BY IDICATION, 2018-2026 ($MILLION)
TABLE 53.  SOUTH AFRICA ANTIFIBRINOLYTIC DRUGS MARKET BY END USER, 2018-2026 ($MILLION)
TABLE 54.  REST OF LAMEA ANTIFIBRINOLYTIC DRUGS MARKET BY IDICATION, 2018-2026 ($MILLION)
TABLE 55.  REST OF LAMEA ANTIFIBRINOLYTIC DRUGS MARKET BY END USER, 2018-2026 ($MILLION)
TABLE 56.  AKORN: COMPANY SNAPSHOT
TABLE 57.  AKORN: OPERATING SEGMENTS
TABLE 58.  AKORN: PRODUCT PORTFOLIO
TABLE 59.  AUROBINDO: COMPANY SNAPSHOT
TABLE 60.  AUROBINDO: OPERATING SEGMENTS
TABLE 61.  AUROBINDO: PRODUCT PORTFOLIO
TABLE 62.  BAYER: COMPANY SNAPSHOT
TABLE 63.  BAYER: OPERATING SEGMENTS
TABLE 64.  BAYER: PRODUCT PORTFOLIO
TABLE 65.  FERRING: COMPANY SNAPSHOT
TABLE 66.  FERRING: PRODUCT PORTFOLIO
TABLE 67.  MYLAN: COMPANY SNAPSHOT
TABLE 68.  MYLAN: OPERATING SEGMENTS
TABLE 69.  MYLAN: PRODUCT PORTFOLIO
TABLE 70.  NOVARTIS AG: COMPANY SNAPSHOT
TABLE 71.  NOVARTIS: OPERATING SEGMENTS
TABLE 72.  NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 73.  PFIZER: COMPANY SNAPSHOT
TABLE 74.  PFIZER: OPERATING SEGMENTS
TABLE 75.  PFIZER: PRODUCT PORTFOLIO
TABLE 76.  SANOFI: COMPANY SNAPSHOT
TABLE 77.  SANOFI: OPERATING SEGMENTS
TABLE 78.  SANOFI: PRODUCT PORTFOLIO
TABLE 79.  TAKEDA: COMPANY SNAPSHOT
TABLE 80.  TAKEDA: OPERATING SEGMENTS
TABLE 81.  TAKEDA: PRODUCT PORTFOLIO
TABLE 82.  VITRUVIAS: COMPANY SNAPSHOT
TABLE 83.  VITRUVIAS: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.  ANTIFIBRINOLYTIC DRUGS, MARKET SEGMENTATION
FIGURE 02.  TOP INVESTMENT POCKETS
FIGURE 03.  TOP PLAYER POSITIONING
FIGURE 04.  DRIVERS, RESTRAINT, AND OPPORTUNITY, ANTIFIBRINOLYTIC DRUGS MARKET
FIGURE 05.  COMPARATIVE SHARE ANALYSIS OF ANTIFIBRINOLYTIC DRUGS MARKET FOR GYNECOLOGY, BY COUNTRY, 2018 & 2026 (%)
FIGURE 06.  COMPARATIVE SHARE ANALYSIS OF ANTIFIBRINOLYTIC DRUGS MARKET FOR HEREDITARY ANGIOEDEMA MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 07.  COMPARATIVE SHARE ANALYSIS OF ANTIFIBRINOLYTIC DRUGS MARKET FOR FIBRINOLYTIC RESPONSE TESTING, BY COUNTRY, 2018 & 2026 (%)
FIGURE 08.  COMPARATIVE SHARE ANALYSIS OF ANTIFIBRINOLYTIC DRUGS MARKET FOR SURGERIES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 09.  COMPARATIVE SHARE ANALYSIS OF ANTIFIBRINOLYTIC DRUGS MARKET FOR OTHERS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 10.  COMPARATIVE SHARE ANALYSIS OF ANTIFIBRINOLYTIC DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11.  COMPARATIVE SHARE ANALYSIS OF ANTIFIBRINOLYTIC DRUGS MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12.  COMPARATIVE SHARE ANALYSIS OF ANTIFIBRINOLYTIC DRUGS MARKET, FOR TRAUMA CENTERS BY COUNTRY, 2018 & 2026 (%)
FIGURE 13.  AKORN: NET SALES, 2016–2018 ($MILLION)
FIGURE 14.  AKORN: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 15.  AUROBINDO: NET SALES, 2016–2018 ($MILLION)
FIGURE 16.  AUROBINDO: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 17.  AUROBINDO: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 18.  BAYER: REVENUE, 2016–2018 ($MILLION)
FIGURE 19.  BAYER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 20.  BAYER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 21.  MYLAN: NET SALES, 2016–2018 ($MILLION)
FIGURE 22.  MYLAN: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 23.  NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 24.  NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 25.  NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 26.  PFIZER: REVENUE, 2016–2018 ($MILLION)
FIGURE 27.  PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 28.  PFIZER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 29.  SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 30.  SANOFI: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 31.  SANOFI: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 32.  TAKEDA: NET SALES, 2016–2018 ($MILLION)
FIGURE 33.  TAKEDA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 34.  TAKEDA: REVENUE SHARE BY REGION, 2018 (%)

 
 

Antifibrinolytic drugs or agents are used in specific situations or in combination with clotting factor replacement to treat hemophilia. These prevent the breakdown of blood clots by counteracting chemicals in the mucous membrane. Antifibrinolytics are increasingly being used in operations associated with high risk of bleeding. These drugs are useful in the management of optimal coagulation. 

The antifibrinolytic drugs market is anticipated to witness a steady growth in the future, owing to its increased usage in patients suffering from hemophilia. In addition, surge in road accidents, accidental traumas, and medical surgeries further contribute to the market growth. However, high cost of these drugs and stringent reimbursement scenario is expected to hamper the growth in the future. Moreover, North America dominated the market in 2018, owing to the surge in cardiovascular surgeries and awareness among women toward usage of these drugs to prevent heavy menstrual flow. Asia-Pacific is anticipated to grow at the fastest rate in the future, owing to significant surge in the number of road accidents. 
 

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, Subscription @ $699 T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The market vaule of global Antifibrinolytic drugs market was $13,593 million in 2018.

A. The forecast period is from 2019 to 2026.

A. The market value of global Antifibrinolytic drugs market in 2019 is $1,4239 million.

A. The adoption of Antifibrinolytic drugs is expected to increase due to rise in its usage to by the females to control heavy menstrual flow.

A. No, the report does not provides value chain analysis.

A. Surge in road accidents across the globe is one of the majo factor boosting the market growth.

A. Emerging countries of Asia-Pacific region are growing at a growth% of 6.1%. India, and China are expected grow at a CAGR of 7.9% and 6.4% respectively.

A. The North America market held a major share in the Antifibrinolytic drugs market in 2018 and is expected to continue the trend in the forecasting period.

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Antifibrinolytic Drugs Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,370
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $0.00
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. Subscription @ $699 T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts